We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Polar Capital Healthcare Opportunities Class I - Income (USD)

Sell:$94.45 Buy:$94.45 Change: $0.68 (0.73%)
Prices as at 4 December 2025
Sell:$94.45
Buy:$94.45
Change: $0.68 (0.73%)
You can buy or sell holdings in this fund through a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
Prices as at 4 December 2025
Sell:$94.45
Buy:$94.45
Change: $0.68 (0.73%)
Prices as at 4 December 2025
You can buy or sell holdings in this fund through a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Asset Allocation

X-ray asset allocation
Key % Net Assets
International Equities 90.36%
Mutual Funds 8.72%
UK Equities 2.29%
Cash and Equiv. -1.37%

Top 10 holdings

Stock name % Weight Country Sector
1 NORTHERN TRUST-US DOLLAR-F 8.72% 003 Managed Funds
2 UCB S.A. 7.63% BEL Pharmaceuticals & Biotechnology
3 ARGENX SE 6.08% NLD Pharmaceuticals & Biotechnology
4 ZEALAND PHARMA A/S 5.25% DNK Pharmaceuticals & Biotechnology
5 FRESENIUS SE & CO. KGAA 4.65% DEU Health Care Providers
6 TEVA PHARMACEUTICAL INDUSTRIES LIMITED 4.04% ISR Pharmaceuticals & Biotechnology
7 BOSTON SCIENTIFIC CORPORATION 3.86% USA Medical Equipment & Services
8 H. LUNDBECK A/S 3.81% DNK Pharmaceuticals & Biotechnology
9 CYTOKINETICS INCORPORATED 3.45% USA Pharmaceuticals & Biotechnology
10 ASCENDIS PHARMA A/S 3.28% DNK Pharmaceuticals & Biotechnology

Fund Analysis is only available on the desktop version of our website. This can be accessed using a desktop or laptop PC or some larger tablets.

You can buy or sell holdings in this fund through a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account